What the studies show
Clinical cohorts show no measurable improvement in gender distress or mental health with puberty blockers. The first Dutch protocol study reported falls in behavior problems and depression (parent-reported clinical-range problems fell from 44% to 22%), but gender distress and body image did not change (de Vries et al., 2011). England's early-intervention study of 44 carefully selected 12–15-year-olds found no change in emotional distress, self-harm, quality of life or gender distress (Carmichael et al., 2021), and a US NIH-funded cohort of 94 youth found no measurable change over two years, with 18% moderately or severely depressed at baseline and 23% at two years (Olson-Kennedy et al., 2025). Formal reviews agree: a meta-analysis of 10 studies rated all mental health, gender distress and bone evidence very low certainty (Miroshnychenko et al., 2025); the York reviews for the Cass Review could draw no conclusions on gender distress or mental health (Cass Review, 2024); and an update of NICE's search found no new qualifying blocker study (Zepf et al., 2024). Blockers also rarely function as a neutral pause: 98% (Carmichael et al., 2021), 87% (Brik et al., 2020) and 100% (de Vries et al., 2011) went on to cross-sex hormones.
Physical outcomes show harm signals. Bone density falls behind peers during suppression; in one re-analysis about a third of patients had abnormally low hip density after two years (Biggs, 2021). At roughly age 28, testosterone-treated females had recovered, while estrogen-treated males retained low spine density, with 9–18% far below the normal range (van der Loos et al., 2023). None of 29 trans women who began blockers in early puberty had mature sperm at surgery (de Nie et al., 2022), and a small preprint reported shrunken, immature testicular tissue (Murugesh et al., 2024). Fertility preservation was rarely used: 2 of 73 teens despite near-universal counseling (Nahata et al., 2017).
Limits of the evidence
No randomized trials exist, and nearly all studies lack an untreated comparison group, so changes cannot be separated from maturation, concurrent therapy or selection. Samples are small, attrition is heavy (37% missing depression data at two years in the US cohort; 14 of 44 remaining at three years in England), and most cohorts are pre-screened, clinic-run and followed only until hormones begin. Bone studies measure density, not fractures; fertility studies examine tissue, not fertility; long-term outcomes are essentially unstudied.